1. An initial manuscript describing this subject has been submitted for publication byB. Gabrielsen, G.R. Pettit, G. Groszek, T.P. Monath, J.W. Huggins, M.J. Phelan, D.F. Kefauver, E.M. Schubert, J. DaRe, B. Ugarkar, M.A. Ussery, M. Hollingshead, J.J. Kirsi, and W.M. Shannon, Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances, J. Nat. Prod., in press.
2. J.W. Huggins, RNA viruses that cause hemorrhagic, encephalitic, and febrile disease, in: “Antiviral Agents and Viral Diseases of Man,” 3rd ed., GJ. Galasso, R.J. Whitley, and T.C. Merigan, eds., Raven Press, Ltd., New York (1990); b) J.W. Huggins, Z.X. Zhang, and T.P. Monath, Inhibition of ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors, Antiviral. Res. S(1):122 (1991).
3. R.W. Sidwell, G.R. Revankar, and R.K. Robins, Ribavirin: review of a broad-spectrum antiviral agent, in: “Viral Chemotherapy,” vol. 2, D. Shugar, Pergamon Press, New York (1985); b) J.W. Huggins, Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug, Revs. Infect. Dis. 11(S4):S750 (1989).
4. G.R. Pettit, C.L. Herald, and C.R. Smith. “Biosynthetic Products for Cancer Chemotherapy,” vol. 6, Elsevier Scientific Pub. Co., Amsterdam (1989); b) G.R. Pettit, V. Gaddamidi, D.L. Herald, S.B. Singh, G.M. Cragg, J.M. Schmidt, F.E. Boettner, M. Williams, and Y. Sagawa, Antineoplastic agents, 120. Pancratium Littorale, J. Nat. Prod. 49(6):995 (1986); c) G.R. Pettit, V. Gaddamidi, and G.M. Cragg, Antineoplastic agents, 105. Zephyranthes grandiflora, J. Nat. Prod. 47(6):1018 (1984).
5. G. Ceriotti, Narciclasine: an antimitotic substance from Narcissus bulbs, Nature 213:595 (1967).